Aminoglycosides have historically been the mainstay of antibiotic therapy in the ICU. Despite the availability of numerous less toxic antibiotics, the clinical and microbiologic attributes of these agents have ensured their continued use in the management of infections in the critically ill patient. Innovative dosing regimens may replace traditional dosing methods if they are shown to provide improved clinical response with less toxicity potential.